On the heels of more positive early data from the lead program derived from its tumor-activated T-cell engager (TRACTr) platform, Janux Therapeutics Inc. inked a collaboration with Bristol Myers Squibb Co. that comes with $50 million in up-front and near-term milestone payments, with the possibility of up to $800 million more tied to development, regulatory and commercial milestones.

In a move that could dramatically shorten some clinical development timelines for drugs targeting multiple myeloma, the U.S. FDA issued a draft guidance on the potential use of minimal residual disease and complete response to support accelerated approvals, following the recommendation of the agency’s Oncologic Drugs Advisory Committee, which voted 12-0 in favor of the change in April 2024.

Another day, another insider trading settlement involving a biopharma company employee. This time the U.S. SEC settlement is with Mohit Verma, who was a researcher and associate director of immunology at the San Diego-based Infinitybio Inc. at the time of the alleged violative trading activity.

Sunshine Lake Pharma Co. Ltd. has patented new PKMYT1 inhibitors reported to be useful for the treatment of cancer, psoriasis and rheumatoid arthritis.

Beyang Therapeutics Co. Ltd. has divulged salts of vascular endothelial growth factor receptor (VEGFR) inhibitors reported to be useful for the treatment of cancer, fibrosis, autoimmune, inflammatory, neurodegeneration, cardiovascular, metabolic and eye disorders.

Shanghai Qingrun Pharmaceutical Technology Co. Ltd. has discovered new GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.

Lunan New Time Biotechnical Co. Ltd. has identified new camptothecin derivatives and their antibody-drug conjugates reported to be useful for the treatment of cancer.